Regencell Bioscience Holdings (RGC) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Regencell Bioscience Holdings (RGC) is Neutral.

The composite score behind that read is -0.13, weighing +0.15 of bullish evidence against -0.23 bearish.

Regencell Bioscience Holdings last closed at $7.11, -3.27% on the session.

Against the IVW growth benchmark the position is -3.11% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

7 graded predictions for RGC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Regencell Bioscience Holdings is classified under Health Care / Pharmaceuticals, with a market capitalisation of $3.64B.

StockMap tracks Regencell Bioscience Holdings as the 28th largest of the 149 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 62 Moderate Underperform, 59 Neutral, 21 Strong Underperform and 7 Moderate Outperform.

On that composite Regencell Bioscience Holdings ranks 50th of 149 in the group, against a group median of -0.27.